Table 1.
Overview of subjects investigated
| Variable | Screening study (n = 50) | Evaluation study (n = 204) | |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 22 (44%) | 97 (48%) | |
| Female | 28 (56%) | 107 (52%) | |
| Age, median (Min-Max) | 40.5 (23–59) | 42 (19–66) | |
| Race, ethnicity, n (%) | |||
| White | 38 (76%) | 201 (98.5%) | |
| Black | 3 (6%) | 0 (0%) | |
| Asian | 8 (16%) | 2 (1%) | |
| Other/unknown | 1 (2%) | 1 (0.5%) | |
| JCPyV VP1 serology, n (%) | |||
| Positive | 36 (72%) | 156 (57%) | |
| Negative | 14 (28%) | 88 (43%) | |
| JCPyV Viruria, n (%) | |||
| Positive* | 13 (26%) | 50 (25%) | |
| Negative | 37 (74%) | 154 (75%) | |
| BKPyV VP1 serology, n (%) | |||
| Positive | n.d. | 178 (88%) | |
| Negative | n.d. | 24 (12%) | |
| JCPyV_VP2_167-15mer serology, n (%) | |||
| Positive | 32 (64%) | 165 (81%) | |
| Negative | 18 (36%) | 39 (19%) | |
*All JCPyV viruric subjects were part of the JCPyV VP1 seropositive subgroup.